Emotional Overeating GLP-1 Agonists: What You Need to Know
Glucagon-like peptide-1 (GLP-1) agonists have revolutionized the treatment of obesity and type 2 diabetes by targeting the body's natural hunger and fullness hormones. These medications have been shown to be effective in reducing body weight and improving glycemic control in individuals with obesity and diabetes. However, the role of GLP-1 agonists in addressing emotional eating behaviors has been a topic of debate.
Understanding Emotional Eating
Emotional eating is a common behavior that involves consuming food in response to emotional stimuli, rather than hunger. This can lead to overeating and weight gain, and can also contribute to the development of eating disorders such as binge eating disorder and bulimia nervosa. GLP-1 agonists, such as semaglutide and liraglutide, have been shown to reduce appetite and increase feelings of fullness, but their effect on emotional eating behaviors is less clear.
Emotional Eating and GLP-1 Agonists
Research has shown that GLP-1 agonists may be less effective in individuals who experience emotional eating behaviors. A study published in Clinical Diabetes and Healthcare found that while GLP-1 agonists were effective in reducing weight and improving glycemic control in individuals who responded to external food cues, they may not be as effective in individuals who experience emotional eating behaviors.
